Relief Therapeutics Holding AG (RLFTF)

[Vanilla Fitbit]

*** 50% PROFIT SHARE NOW DOWN TO 2.5% ****

AS IVE SAID ALL ALONG.... RAM, JACK, AND THE REST OF RELIEF MANAGEMENT TOP TO BOTTOM IS ABSOLUTELY ABYSMAL!!!!!

**** YOU REALIZE THAT PER AGREEMENT RELIEF’s % OF PROFITS ON EVERYTHING NON COVID DROPS TO ONLY 2.5% WHEN THEY DIDNT FUND TRIAL/FORMULATION... AND REMEMBER HOW EVERYONE SAYS “THIS IS SO MUCH MORE THAN JUST COVID”******



As of the date of this filing, Relief has reimbursed NRx Pharmaceuticals $10,904,065 for expenses, but has subsequently declined to pay approximately $6 million in invoiced costs associated with conduct of the IV clinical trial, reformulation, and manufacture of ZYESAMITM. Relief has additionally declined to fund the costs of the inhaled trial. NRx Pharmaceuticals advised Relief that NRx Pharmaceuticals is funding those costs with other capital. NRx Pharmaceuticals further advised Relief in December 2020 that the formulation data provided to NRx Pharmaceuticals as part of the collaboration agreement was non-reproducible. Relief subsequently issued a public disclosure acknowledging that Relief knew about the stability problems at the time of the collaboration agreement. Relief declined to fund the development of a stable formulation.


5.4.
If NeuroRx or any of its Affiliates seeks to develop itself or collaborate with another Person on any treatment for acute respiratory distress syndrome, acute lung injury, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, sarcoidosis, and influenza, regardless of MOA, which, in each case, is non-COVID related, then: (a) if Relief provides all funding, it shall be entitled to 50% of NeuroRx’s Net Profits, and (b) if Relief does not provide all funding, it shall be entitled to 2.5% of NeuroRx’s Net Profits.